A meta-analysis of eight randomized controlled trials proved that GLP-1R agonists, regardless of molecular structure, reduced the risk of major acute cardiovascular events, all-cause mortality, hospitalizations for heart failure, and worsening kidney function in patients with type 2 diabetes; thus, GLP-1R-based therapies represent an important method to reduce the mortality and morbidity in diabetic patients [164]. Here, GLP1R is linked to heart failure.